NCT02176122 arm group 649e2341cd89f077f9af484ac7bc63a0 [clinicaltrials_resource:NCT02176122/arm-group/649e2341cd89f077f9af484ac7bc63a0]
arm group [clinicaltrials_vocabulary:arm-group]
NCT02176122 arm group 649e2341cd89f077f9af484ac7bc63a0 [clinicaltrials_resource:NCT02176122/arm-group/649e2341cd89f077f9af484ac7bc63a0]
Bio2RDF identifier
NCT02176122/arm-group/649e2341cd89f077f9af484ac7bc63a0
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 9e2341cd89f077f9af484ac7bc63a0
description [clinicaltrials_vocabulary:description]
Piperacillin/tazobactam 4.5g adm every 6 hours IV up to study day 4.
identifier
clinicaltrials_resource:NCT02176122/arm-group/649e2341cd89f077f9af484ac7bc63a0
title
NCT02176122 arm group 649e2341cd89f077f9af484ac7bc63a0
@en
type
label
NCT02176122 arm group 649e2341 ...... e2341cd89f077f9af484ac7bc63a0]
@en